Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

69
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
69
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

199
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
199
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.0K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

168
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
168
Pharmacovigilance01:19

Pharmacovigilance

891
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
891

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive accuracy of gait speed for falls: An individual participant data meta-analysis.

Ageing research reviews·2026
Same author

Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.

Neurology·2026
Same author

Peer-assisted telemedicine for hepatitis C intervention in people experiencing housing instability.

Harm reduction journal·2026
Same author

Stop the Spin: Confronting Reporting Bias in Multiple Sclerosis Research.

Annals of neurology·2026
Same author

Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?

Neurology·2025
Same author

Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program.

Neurology. Clinical practice·2025

Related Experiment Video

Updated: Jul 20, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.

W Daniel Chapman1, Megan C Herink2, Michelle H Cameron3

  • 1Department of Neurology, Oregon Health & Science University, Portland, OR, USA. wdanielchapman@gmail.com.

Current Neurology and Neuroscience Reports
|July 31, 2023
PubMed
Summary
This summary is machine-generated.

Polypharmacy, using 5+ medications, is common in multiple sclerosis (MS) and linked to poor outcomes. Healthcare providers should assess medication appropriateness and risks to mitigate harm in MS patients.

Keywords:
Anticholinergic BurdenDeprescribingMultiple SclerosisPolypharmacySymptomatic Treatment

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.5K

Related Experiment Videos

Last Updated: Jul 20, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.5K

Area of Science:

  • Neurology
  • Pharmacology
  • Patient Safety

Background:

  • Polypharmacy (≥5 medications) is prevalent in multiple sclerosis (MS) patients.
  • Multiple medications are used for MS symptom management, increasing risks.
  • These risks include drug-drug interactions and additive side effects.

Purpose of the Study:

  • To review the prevalence and risks of polypharmacy in multiple sclerosis.
  • To offer strategies for identifying and mitigating inappropriate polypharmacy.
  • To guide healthcare providers in optimizing pharmacotherapy for MS patients.

Main Methods:

  • Literature review of research on polypharmacy in multiple sclerosis.
  • Analysis of medication class-specific contributions to inappropriate polypharmacy.
  • Identification of risk factors and negative outcomes associated with polypharmacy in MS.

Main Results:

  • Polypharmacy is common and associated with negative outcomes in multiple sclerosis.
  • Specific medication classes contribute to potentially inappropriate polypharmacy.
  • Multiple sclerosis patients are at significant risk for polypharmacy-related issues.

Conclusions:

  • Multiple sclerosis providers must evaluate pharmacotherapy appropriateness and risks.
  • Deprescribing should be considered within the context of individual patient needs.
  • Mitigating polypharmacy is crucial for improving patient outcomes in multiple sclerosis.